

**PRESS RELEASE**

**Ad hoc announcement pursuant to article 53 LR**

## **LEPU Medical Technology(Beijing) Announces Results for the Third Quarter of 2023**

In the third quarter, the Company realized an operating income of RMB 1957.7701 million. A net profit of RMB 392.1135 million attributable to the shareholders in listed companies. The net profit attributable to shareholders of listed companies after the non-recurring gains and losses were deducted was RMB 381.0554 million; The expenses related to equity incentives implemented by the Company were excluded, the net profit attributable to shareholders of listed companies after the non-recurring gains and losses were deducted was RMB 422.5170 million. In the third quarter, the Company realized a net operating cash flow of RMB 462.0806 million. The specific financial data were as follows:

During the reporting period, the Company's accumulated operating income was RMB 6259.2278 million, decreased by RMB 1502.5713 million compared with the same period of last year, with a decrease of 19.36%. The main reason was the high base of emergency business in the same period last year due to COVID-19.

1) As the sector with the largest proportion of the Company's operating income, medical devices realized an operating income of RMB 2863.4159 million during the reporting period. The Company's innovative product portfolios of intervention still achieved growth. During the reporting period, the operating income of innovative product portfolio has a year-on-year increase of 6.08%. Benefiting from the domestic substitution brought by the policy of volume-based procurement, the Company's surgical anesthesia business maintained a good growth trend, and the operating income of surgical anesthesia business increased by 6.91% year-on-year during the reporting period.

2) In the pharmaceutical sector, the operating income was basically steady in the third quarter, with an accumulated decrease of 5.92% during the reporting period.

3) The medical service and health management sectors were new business sectors actively cultivated by the Company. This business is an innovative business of the Company, with constantly increasing investment. In the future, the business will rely on the advantages of data and technology to continuously expand its sales channels. In the reporting period, the medical service and health management sector realized an operating income of RMB 979.5734 million.

### Financial Results(unaudited)

	Three Months Ended September 30, 2022	% Change	Nine Months Ended September 30, 2022	% Change
Operating revenue(RMB)	1,957,770,143.63	-19.38%	6,259,227,849.28	-19.36%
Net profit attributable to shareholders of the Company (RMB)	392,113,517.73	-27.66%	1,353,600,791.72	-25.22%
Net profit attributable to shareholders of the Company after deducting non-recurring profit and loss (RMB)	381,055,371.61	-29.60%	1,285,930,081.17	-28.75%
Basic earnings per share (RMB /share)	0.2105	-30.76%	0.7268	-28.45%
Diluted earnings per share (RMB /share)	0.2105	-30.21%	0.7257	-27.80%
Return on weighted average net assets	2.46%	-1.93%	8.84%	-6.20%

## **Full third quarter report**

The full three-quarter results report as of and for the nine months ended September 30, 2023 is available on our website at <https://en.lepumedical.com/investors/>.

## **Contact information**

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: [zqb@lepumedical.com](mailto:zqb@lepumedical.com)

## **About LEPU**

LEPU Medical Technology(Beijing) Co.,Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions Company is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D expertise and capabilities have enabled us to develop and successfully commercialize a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary

artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

## **Disclaimers**

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.